GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Cyclically Adjusted PS Ratio

Blueprint Medicines (FRA:2L9) Cyclically Adjusted PS Ratio : 27.67 (As of Jun. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Cyclically Adjusted PS Ratio?

As of today (2024-06-19), Blueprint Medicines's current share price is €96.00. Blueprint Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €3.47. Blueprint Medicines's Cyclically Adjusted PS Ratio for today is 27.67.

The historical rank and industry rank for Blueprint Medicines's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:2L9' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 12.63   Med: 23.84   Max: 28.21
Current: 27.3

During the past years, Blueprint Medicines's highest Cyclically Adjusted PS Ratio was 28.21. The lowest was 12.63. And the median was 23.84.

FRA:2L9's Cyclically Adjusted PS Ratio is ranked worse than
87.72% of 505 companies
in the Biotechnology industry
Industry Median: 5.29 vs FRA:2L9: 27.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Blueprint Medicines's adjusted revenue per share data for the three months ended in Mar. 2024 was €1.386. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €3.47 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Blueprint Medicines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Cyclically Adjusted PS Ratio Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 25.09

Blueprint Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 13.73 25.09 24.93

Competitive Comparison of Blueprint Medicines's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Blueprint Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Cyclically Adjusted PS Ratio falls into.



Blueprint Medicines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Blueprint Medicines's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=96.00/3.47
=27.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Blueprint Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Blueprint Medicines's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.386/131.7762*131.7762
=1.386

Current CPI (Mar. 2024) = 131.7762.

Blueprint Medicines Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.024 99.621 0.032
201506 0.140 100.684 0.183
201509 0.114 100.392 0.150
201512 0.157 99.792 0.207
201603 0.227 100.470 0.298
201606 0.231 101.688 0.299
201609 0.201 101.861 0.260
201612 0.256 101.863 0.331
201703 0.165 102.862 0.211
201706 0.135 103.349 0.172
201709 0.173 104.136 0.219
201712 0.034 104.011 0.043
201803 0.018 105.290 0.023
201806 0.809 106.317 1.003
201809 0.021 106.507 0.026
201812 0.021 105.998 0.026
201903 0.015 107.251 0.018
201906 0.093 108.070 0.113
201909 0.170 108.329 0.207
201912 0.942 108.420 1.145
202003 0.106 108.902 0.128
202006 0.137 108.767 0.166
202009 11.140 109.815 13.368
202012 0.482 109.897 0.578
202103 0.312 111.754 0.368
202106 0.388 114.631 0.446
202109 0.351 115.734 0.400
202112 1.606 117.630 1.799
202203 0.960 121.301 1.043
202206 0.580 125.017 0.611
202209 1.115 125.227 1.173
202212 0.611 125.222 0.643
202303 0.983 127.348 1.017
202306 0.878 128.729 0.899
202309 0.873 129.860 0.886
202312 1.084 129.419 1.104
202403 1.386 131.776 1.386

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (FRA:2L9) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Blueprint Medicines Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (FRA:2L9) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines